Excerpts from the Pear Therapeutics Report.

Issue 019.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 68 percent open rate. Here's what's happening this week:

After weeks of research, I am excited to push live The Pear Therapeutics Report. More on that below, but don't miss this one. Lots of scoops. Anyone working in, partnering with, or investing in digital therapeutics needs to understand Pear Therapeutics in depth. This 4,500-word report is the best way to start.
Cognoa, which is developing digital therapeutics for the diagnosis and treatment of autism, inked an important partnership with Eversana that sheds some like on the DTx company's commercialization strategy. Eversana will act as a hub that helps with adjudication and delivery of Cognoa's digital therapeutics.
Hinge Health, which offers musculoskeletal-focused digital therapeutic programs, now has

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Excerpts from the Pear Therapeutics Report.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.